Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
CAMBRIDGE, Mass., Feb. 11, 2016 -- Proteostasis Therapeutics, Inc. today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $8.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Proteostasis Therapeutics, Inc. In addition, the company has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock from the company at the public offering price. The company’s shares are expected to begin trading on the NASDAQ Global Market on February 11, 2016 under the ticker symbol “PTI.” The offering is expected to close on February 17, 2016 subject to customary closing conditions.
Leerink Partners and RBC Capital Markets are acting as joint book-running managers. Baird and H.C. Wainwright & Co. are acting as co-managers.
A registration statement relating to the securities being sold in the offering was declared effective by the Securities and Exchange Commission on February 10, 2016. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting: Leerink Partners LLC, c/o Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by email at [email protected], or by phone at (800) 808-7525, ext. 6142; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, Telephone: (877) 822-4089, Email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contact: Dan Budwick, Pure Communications [email protected] 973-271-6085 Investor Contact: Luke Heagle, Pure Communications [email protected] 910-726-1372
